morning traders 19/07, page-190

RHT


Resonance Health Limited (ASX: RHT) (“Resonance Health” or the “Company&rdquo is pleased to announce that it has executed a Master Services Agreement (“MSA&rdquo and an associated initial Scope of Work with a US NASDAQ-listed pharmaceutical company (the “Client&rdquo for the use of Resonance Health products and services in their clinical trial. The clinical trial covered under the initial Scope of Work will commence in July 2019 and continue for a period of 48 months. This period may be extended, for example if the clinical trial takes longer than expected. As consideration for satisfactorily performing the services in the initial Scope of Work, the Company will be paid approximately US $1 million over the duration of the trial.